BIOMAT Database Logo BIOMAT Database Logo

Adverse events during treatment with recombinant insulin-like growth factor I in patients with growth hormone insensitivity. 1994

M B Ranke, and P Wilton
Section of Paediatric Endocrinology, Children's Hospital, University of Tübingen, Germany.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin

Related Publications

M B Ranke, and P Wilton
Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity.
April 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement,
M B Ranke, and P Wilton
Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I).
July 1996, Bailliere's clinical endocrinology and metabolism,
M B Ranke, and P Wilton
Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
September 1992, Acta paediatrica (Oslo, Norway : 1992). Supplement,
M B Ranke, and P Wilton
Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS).
April 1999, Journal of pediatric endocrinology & metabolism : JPEM,
M B Ranke, and P Wilton
Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
March 2008, Pediatric endocrinology reviews : PER,
M B Ranke, and P Wilton
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
March 2007, The Journal of clinical endocrinology and metabolism,
M B Ranke, and P Wilton
The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
July 1993, Clinical endocrinology,
M B Ranke, and P Wilton
Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome.
June 1993, Clinical endocrinology,
M B Ranke, and P Wilton
Therapy with recombinant human insulin-like growth factor I in children with insensitivity to growth hormone and in catabolic conditions.
December 1993, Journal of internal medicine,
M B Ranke, and P Wilton
Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
January 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!